Back to homepage

Gastroenterology

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Authors: Benjamin Crooks MA MBBS, Tom Barnes MBBS BSc, Jimmy K Limdi FRCP FACG

This review brings together data reported on VDZ to date for treatment of inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC).

More

Gastroesophageal reflux in children: an updated review

Authors: Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM

This review article provides an update on the current understanding, evaluation, and management of gastroesophageal reflux in children.

More

New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance

Authors: Kartikeya Tripathi MD, Joseph D Feuerstein MD

Ulcerative colitis is a chronic idiopathic inflammatory disorder that involves any part of the colon. The authors review the latest evidence on management, treatment, and maintenance.

More

Second-line treatment options in hepatocellular carcinoma

Authors: Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

More

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Authors: Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).

More